Ocular corrections are nowadays relying on the intraocular lenses (IOLs), which are utilized as refractive lens exchange for eyes that have undergone vision loss due to changes in the naturally existing eye lens. The global intraocular lens market by the Asia Pacific is predicted to proliferate at a CAGR of 5.64% between 2019 and 2027 to generate revenue of $XX million by 2027.
The Asia-Pacific regional market study covers the economies of Japan, China, India, Australia, South Korea, and other countries forming the collective regional segment of the Rest of World. The multiple lucrative opportunities that are provided by the intraocular lens market in the densely populated region of APAC are projected to drive the market growth at the fastest pace during the forecast period.
Growing prevalence of cataract, the surge in minimally invasive procedures demand and the technological advancements are the major driving factors that are advancing the market penetration significantly during the forecasting years.
Johnson & Johnson, Inc., Santen Pharmaceutical Co., Ltd., Lenstec, Inc., Pfizer, Bausch Health Companies Inc. (formerly Valent Pharmaceuticals International Inc.), Abbott Medical Optics, Inc. (subsidiary of Abbott Laboratories, Inc.), Essilor International S.A., Eyekon Medical Inc., Alcon, Hoya Corporation, Carl Zeiss AG, Staar Surgical Company, HumanOptics AG, and Rayner Intraocular Lenses Ltd. are the major companies operating in the market.